Clinical trials: Immunogenicity, Vaccine
Influenza
Safety and Immunogenicity of Influenza H9 Vaccine in Humans
H9N2 influenza circulates in animal and poultry and has caused delf limiting infections in children. Influenza H9N2 poses a pandemic threat to humans.
- Trial name
- NCT00814229
- Testing
- H9N2 whole virus vaccine, IM, 1.5microg, H9N2 whole virus vaccine, IM, 5microg, H9N2 whole virus vaccine vaccine, IM, 15microg
- Where
- United Kingdom
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- University Hospitals, Leicester
Staphylococcal Infections
V710 First-In-Man (FIM) Study (V710-001)
This is a randomized, Multicenter, double-blind (subject, investigator, and Merck Research Laboratories (MRL) clinical personnel directly involved in the study), placebo-controlled, dose-ranging study in healthy adults 18 to 55…
- Trial name
- NCT00303069
- Testing
- V710
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Meningococcal Immunisation, Healthy Volunteers
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
This study evaluated the immunogenicity and safety of a single dose of MenQuadfi® administered as a booster vaccine in toddlers 12 - 23 months of age in Argentina who had been primed with at least 1 dose of the quadrivalent…
- Trial name
- NCT05929651
- Testing
- MenACYW conjugate vaccine
- Where
- 2 sites in Argentina
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Plasmodium Falciparum Malaria, Vaccines
Experimental Vaccine for Plasmodium Falciparum Malaria
This study will evaluate the safety of two experimental malaria vaccines in healthy volunteers and examine their immune response to them.
- Trial name
- NCT00340431
- Testing
- MSP1(42)-FVO & MSP1(42)-3D7
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Poliomyelitis
Immunogenicity nOPV2 With and Without bOPV
This is an open-label randomized clinical trial that will compare immune responses among infants who receive either novel monovalent oral poliovirus vaccine type 2 (nOPV2) alone, bivalent oral poliovirus vaccine (bOPV) alone, or…
- Trial name
- NCT04579510
- Testing
- Novel monovalent oral poliovirus vaccine type 2 (nOPV2), Bivalent oral poliovirus vaccine (bOPV)
- Where
- Bangladesh
- Volunteers
- 795 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Herpes Zoster
Prevention of Varicella Zoster Virus (VZV)-Reactivation in HIV-positive Individuals Enrolled in a Prospective Immunogenicity and Safety Trial of VZV Vaccine: PROVE-IT-Study
The goal is to demonstrate the immunogenicity and safety of Zostavax® in HIV positive individuals. Study participants are stratified into different patient groups according to their CD4 cell count, viral load and HIV Status.
- Trial name
- NCT01213810
- Testing
- Zostavax
- Sponsor
- University of Zurich
Poliomyelitis
Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine
The goal of this study is to compare the immunogenicity and safety of sIPV administered via subcutaneous and intramuscular injection routes
- Trial name
- NCT07457060
- Testing
- 2wIPV+1sIPV, 1wIPV+2sIPV, 3wIPV
- Where
- 3 sites in Philippines
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Malaria,Falciparum
Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso
This is a double blind randomised controlled clinical trial to evaluate the efficacy of R21 adjuvanted with Matrix-M in healthy 5-17 month old children in a malaria endemic area.
- Trial name
- NCT03896724
- Testing
- R21 adjuvanted with 25mcg Matrix-M, Rabies Vaccine, R21 adjuvanted with 50mcg Matrix-M
- Where
- Burkina Faso
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Human Papillomavirus Infection
A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)
This was a 37-month safety and immunogenicity study conducted in boys and girls 9 to 14 years of age and in young women 16 to 26 years of age.
- Trial name
- NCT01984697
- Testing
- V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)
- Volunteers
- 1,518 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants
This study evaluated the safety and immune response in healthy HIV-exposed and uninfected infants to the protein vaccine, CH505TF gp120, adjuvanted with GLA-SE.
- Trial name
- HVTN 135 (NCT04607408)
- Testing
- CH505TF gp120, GLA-SE adjuvant
- Where
- South Africa
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- HIV Vaccine Trials Network
Influenza, Influenza, Human
Revaccination With Influenza Vaccine GSK1247446A
The protocol is designed to demonstrate the safety of influenza vaccine GSK1247446A after revaccination.
- Trial name
- NCT00545025
- Testing
- Influenza Vaccine GSK1247446A, Fluarix™
- Where
- Belgium
- Volunteers
- 243 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old
This study will assess safety and immunogenicity of GSK Biologicals' H5N1 flu candidate vaccines GSK2590066A and GSK2340273A in healthy adults 18 - 49 years old.
- Trial name
- NCT01236040
- Testing
- GSK Biologicals' investigational vaccine GSK2590066A, GSK Biologicals' investigational vaccine GSK2592984A, GSK Biologicals' investigational vaccine GSK2340274A
- Where
- 4 sites in United States
- Volunteers
- 521 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Experimental Vaccine for Malaria
This study will examine the safety and immune response of healthy adult volunteers to AMA1-C1, an experimental malaria vaccine developed by the NIAID.
- Trial name
- NCT00114010
- Testing
- AMA1/Alhydrogel
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Zoster
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in adults ≥ 65 years of age with and without Zostavax® vaccination at least 5 years earlier.
- Trial name
- NCT02581410
- Testing
- GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
- Where
- 32 sites in United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chickenpox
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
This study aims to assess the immune response and safety of GSK's candidate chickenpox and marketed MMR vaccines when given to children 12 to 15 months of age via a muscle injection.
- Trial name
- NCT06855160
- Testing
- Candidate varicella vaccine, Marketed varicella vaccine, MMR vaccine
- Where
- 22 sites in United States, Belgium and 5 more
- Volunteers
- 911 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)
To determine the safety of vaccinia-derived HIV-1 recombinant envelope glycoprotein (gp160) in human volunteers; to evaluate the immunogenicity of this preparation in human volunteers.
- Trial name
- NCT00000968
- Testing
- gp160 Vaccine (Immuno-AG)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acellular Pertussis, Poliomyelitis
Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults
This study will evaluate the persistence of immune response against diphtheria, tetanus, pertussis and poliomyelitis in healthy adults, 10 years after a booster dose, and also assess the immunogenicity and safety of another…
- Conditions
- Acellular Pertussis, Poliomyelitis, Diphtheria, Tetanus
- Trial name
- NCT01323959
- Testing
- BoostrixTM Polio
- Where
- 15 sites in France, Germany
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acne
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
The purpose of the trial is to evaluate the safety, efficacy and immunogenicity of up to 3 intramuscular injections of the Acne mRNA vaccine candidate at up to four dose levels in adult participants aged 18 to 45 years with…
- Trial name
- NCT06316297
- Testing
- Acne mRNA vaccine
- Where
- 94 sites in United States, Australia and 2 more
- Volunteers
- 800 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy Adult Female Participants, Prevention
A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)
This study was conducted to assess the safety, immunogenicity, efficacy and long-term effectiveness of a vaccine being evaluated for the prevention of human papillomavirus (HPV) infection and disease in mid-adult women.
- Conditions
- Healthy Adult Female Participants, Prevention, Papillomavirus Infection, Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
- Trial name
- NCT00090220
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 3,819 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diphtheria Vaccine Adverse Reaction, Tetanus Vaccine Adverse Reaction
Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma)
This bridging study is a randomized, double-blind, two arms parallel group, prospective intervention study. The primary objective of this study is to evaluate protectivity of DTP-HB-Hib Vaccine (Bio Farma) using new Hepatitis B…
- Conditions
- Diphtheria Vaccine Adverse Reaction, Tetanus Vaccine Adverse Reaction, Pertussis Vaccine Adverse Reaction, Haemophilus Influenzae Type B Vaccine Adverse Reaction
- Trial name
- NCT05482282
- Testing
- Recombinant Hepatitis B new Bulk vaccine, DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine, Recombinant Hepatitis B vaccine (Registered BioFarma)
- Where
- 3 sites in Indonesia
- Volunteers
- healthy volunteers welcome
- Sponsor
- PT Bio Farma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.